Clinical course and related costs of patients with type 2 diabetes and heart failure and/or chronic kidney disease, drawn from a sample of more than 7 million people
A comprehensive characterization of acute heart failure with preserved vs. mildly reduced vs. reduced ejection fraction: insights from the ESC-HFA EORP Heart Failure Long-Term Registry
Eligibility for dapagliflozin and empagliflozin in real-world heart failure based on DAPA-HF, DELIVER, EMPEROR-Reduced and EMPEROR-Preserved selection criteria
Speaker:
Associate Professor G. Savarese (Stockholm, SE)
The risk of all-cause death after COVID-19 hospital admission among patients with prior heart failure, chronic kidney disease and cardiorenal syndrome: a 12 month follow-up observational study
Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs. reduced ejection fraction based on the 2021 definition and classification of heart failure